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Pharmacokinetics of gentamicin in the treatment of renal infec-
tion: A therapeutic anomaly explained. A model of pyelonephritis
was used to investigate the ability of gentamicin to eradicate ex-
perimental renal infection. Escherichia colt pyelonephritis was
induced in 56 rats, and treatment with gentamicin was started 7
days after challenge and was maintained for 11 days. Renal tissue
examined at autopsy 14 days after the final dose of gentamicin
was found to be sterile on initial culture. Dilution of the homoge-
nized preparations of renal tissue before culture, however, re-
vealed that substantial numbers of E. colt had survived, in fact,
and up to 2.5 x 105E. coli could be demonstrated in the kidney in
this way. An explanation for this observation was found when it
was shown that bactericidal concentrations of gentamicin could
be demonstrated in the renal cortex up to 14 days after the final
administration. Renal cortical tissue was sterile in 88% of the
tissue examined, but bacterial persistence was found in the me-
dulla (29% sterile) where the concentration of gentamicin was
comparatively low. Thus, a reciprocal relationship between the
site of bacterial persistence and the concentration of anti-
microbial agent in the kidney indicates how infection of the renal
parenchyma can be maintained despite the presence of an appar-
ent overall bactericidal concentration of gentamicin. These ex-
periments demonstrate the importance of relating the pharma-
cokinetics of the antimicrobial agent and the bacteriologic fea-
tures of the disease to local and anatomic characteristics of the
kidney in the treatment of pyelonephritis.
Pharmacocinetique de Ia gentamycine dans le traitement de
l'infection rénale. Un modèle de pyelonephrite a été utilisé au
cours d'expériences o6 Ia capacité de Ia gentamycine a éradi-
quer l'infection rénale a été étudiee. Des pyelonéphrites a Es-
cherichia colt ont été induites chez 56 rats et le traitement par Ia
gentamycine a été entrepris au 7ème jour et poursuivi pendant 11
jours. Le tissu renal a été examine a l'autopsie, l4jours après la
dernière administration de gentamycine, et il était sterile a Ia
premiere culture. La dilution des preparations de tissu renal
homogenéisees avant Ia culture a revdlé que E. colt, en nombre
important, survit en fait et que jusqu'à 2,5 x lO E. coli
pouvaient être mis en evidence de cette facon. Une explication a
cette constatation a été obtenue quand il a étë montré que des
concentrations bactéricides de gentamycine sont encore pré-
sentes dans le tissu renal 14 jours après Ia cessation de
l'administration. Le tissu renal cortical était sterile dans
88% des tissus examines mais Ia persistance bactérienne a été
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observée dans Ia médullaire (sterile dans 29% des échantillons)
oü Ia concentration de gentamycine est comparativement faible.
Ainsi une relation reciproque entre Ic site de Ia persistance bac-
térienne et Ia concentration de l'agent antimicrobien dans Ic rein
indique comment l'infection du parenchyme renal peut se main-
tenir malgré la presence d'une concentration globale bactericide
de gentamycine. Ces experiences démontrent l'importance qu'il
y a a relier Ia pharmacocinetique de l'agent antimicrobien et les
caractéristiques bactériologiques de Ia maladie aux caractéris-
tiques locales et anatomiques du rein dans Ic traitement de Ia pyé-
lonéphrite.
The failure to eradicate renal infection by anti-
microbial therapy is a problem commonly encoun-
tered in clinical practice. The fact that 25 to 50% of
patients with urinary tract infection may have renal
parenchymal infection and the frequency with
which urinary tract infections recur 1—5j under-
score the need for a continuing evaluation of the bio-
logic basis of antimicrobial therapy.
An incidental observation in the course of recent
experiments involving attempts to treat experimen-
tally induced renal infection with gentamicin led us
to suspect that despite apparently effective gen-
tamicin treatment many viable microorganisms (Es-
cherichia co/i) remained in renal tissue. This was
confirmed in further experiments where a reciprocal
relationship between the persistence of infection in
the renal cortex and medulla and the concentration
of the antimicrobial agent in these tissues was
shown. Thus, it has been possible to offer
an explanation for the clinical observation of an ap-
propriately selected and administered antimicrobial
agent that has apparently failed to eradicate renal
infection.
Methods
Experimental animals. Female animals weighing
between 220 and 250 g were obtained from a ran-
dom-bred strain of Wistar rat.
Experimental renal infection. Pyelonephritis was
induced by the direct inoculation of E. co/i 075 into
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the surgically exposed kidney. Details of the meth-
od have been given previously 161.
Gentamicin administration. Gentamicin, 15 mgI
kg, was injected i.m. daily for 11 days, beginning 1
week after the initiation of infection. Animals were
killed 1, 4, 7, 11, 14, and 18 days after the termi-
nation of gentamicin treatment.
Sensitivity of the E. coli 075 to gentamicin. The
minimum inhibitory and bactericidal concentration
of gentamicin was determined to be 1.6 g/ml.
Bacterial content of renal tissue. Kidneys were
removed with a sterile procedure and homogenized
in 5 ml of sterile saline. Nutrient agar pour plates
were made from serial two-fold dilutions to obtain
the bacterial count per gram of wet renal tissue. In
reporting the bacteriologic data, the maximum num-
ber of E. co/i found in the tissue samples was re-
corded at all times.
Tissue, blood, and urine preparation. Animals
were killed in a carbon dioxide chamber, and the
kidneys were removed immediately and decapsu-
lated in sterile petri dishes. The medulla with at-
tached papilla from each kidney was removed with
a hollow cylindrical blade of 7-mm internal diame-
ter. Cortical tissue on each side of the medullary
cylinder was removed, and the crescent of cortex
left after removal of the medullary plug was
trimmed to remove residual medullary tissue. By
this procedure it was possible to selectively dissect
the entire kidney into cortical and medullary tissue.
Tissue samples were weighed before being homoge-
nized in 5 ml of sterile saline, and the homogenate
was centrifuged to deposit tissue debris. The pH of
the supernatant fluid was adjusted to a pH of 8.0
prior to analysis. Blood samples were collected ei-
ther by venipuncture from a tail vein or by heart
puncture at sacrifice. Samples of serum were ana-
lyzed immediately or stored at —70° C.
Antibiotic assays. The concentration of gen-
tamicin in serum, urine, and tissue samples was de-
termined by an agar-well-diffusion procedure as de-
scribed by Bell and Wood 171. Assays were carried
out in duplicate with Bacterium subtilis as the in-
dicator strain. The assay plate consisted of a 30-cm-
square base of 6-mm-thick plate glass with a 50-mm-
wide frame of the same glass on top. Difco antibiot-
ic medium 11 agar (110 ml; pH, 8) containing 1 ml of
B. subtilis was poured onto the warmed plate, a
small amount seeping between the two plates to
form a seal. Zones of inhibition by test samples
were compared with a standard curve drawn from
the zones of inhibition produced by seven known
concentrations of gentamicin (0.06 to 5 gIml) pre-
pared in a pH-8 buffer and diluted in normal serum.
The diameters of the zones of inhibition were
plotted on semilogarithmic paper, and the concen-
trations of antibiotics in the test samples were ob-
tained directly from the standard curve. Serum con-
centrations were expressed as micrograms per mil-
liliter, and the tissue concentration as micrograms
per gram of tissue.
Methodologic controls. No antibacterial activity
could be demonstrated when homogenates of kid-
ney from untreated animals were examined. Pos-
sible binding of gentamicin to cortical and medul-
lary tissue was also investigated. Recovery of gen-
tamicin added to tissue homogenates was
quantitative, thus failing to demonstrate binding
within the range of concentrations encountered in
these experiments, and no correction factor was
necessary.
Results
Pyelonephritis. Injection of E. co/i into the kid-
ney with a glass microcapillary resulted in a consis-
tent and reproducible infection in the renal paren-
chyma. The earliest gross pathologic changes were
detected on the 4th day after infection. Lesions
originated along the line of inoculation and extend-
ed from the cortex into the medulla of the kidney.
Histologic evidence of active renal infection was
detected 48 hr after the challenge. As the infection
progressed, pitted and scarred areas characteristic
of chronic pyelonephritis developed. (See Ref. 8 for
photograph of gross changes.)
Apparent eradication of renal infection by gen-
tamicin therapy. Experimental pyelonephritis was
induced in a group of 56 animals which were sub-
sequently treated with gentamicin for 11 days start-
ing 7 days after challenge. The concentration of
gentamicin in serum was determined at 30-mm in-
tervals over a 2.5-hr period after the administration
of gentamicin, 15 mg/kg. Urine samples were ob-
tained over a 24-hr period in a split collection made
during the first 10-hr and the final 14-hr period, and
the gentamicin concentrations of the samples were
determined (Fig. 1). Thirty days after the initiation
of infection the animals were killed, and the kidneys
were removed for bacteriologic examination. Ho-
mogenates of renal tissue examined at autopsy 14
days after the final dose of gentamicin were found to
be sterile on bacteriologic culture. Dilution of the
homogenized preparations of renal tissue before in-
corporation into nutrient agar pour plates, however,
revealed that a substantial number of viable E. coli
had survived in the kidney. Of the 56 animals in this
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kidney (Fig. 3). When gentamicin concentrations in
serum and urine were followed over the same peri-
od in a further group of 49 animals, gentamicin was
barely detectable in the serum (<0.02 tg/mI) 24 hr
after the final administration, whereas bactericidal
concentrations of the antimicrobial agent could be
demonstrated in the urine up to 7 days after cessa-
tion of therapy and were still detectable 18 days lat-
er (Fig. 4).
Does renal infection influence the intrarenal dis-
tribution of gentamicin? In the previous experi-
T ment, renal infection did not affect the accumula-
tion of gentamicin by renal tissue. The fact that the
lesion established involved a relatively small
amount of renal tissue compared with the amount of
normal tissue remaining may have obscured any dif-
ference. In the present experiment, the effect of
renal infection on the intrarenal distribution of gen-
tamicin was studied. A lesion was established in the
upper pole of the kidney in 32 rats by the direct in-
oculation of E. co/i. Gentamicin administration be-
experiment that were challenged with E. co/i 075
and treated with gentamicin, only 15 were in fact
sterile when dilutions of homogenate were cultured.
Of the remaining 41 animals, 37 showed a signifi-
cant increase in microorganisms recoverable with
dilution, and a maximum increase in bacterial num-
bers of log10 1.1 to 5.4 (mean, 2.6) was found (Fig.
2). In control experiments with untreated animals,
no increase in the bacterial content of kidney tissue
was found when homogenates subjected to the
same procedure were analyzed.
Does gentamicin accumulate in renal tissue in
pyelonephritis? An inhibitory concentration of gen-
tamicin in the pyelonephritic kidney was a likely ex-
planation for the results observed. This possibility
was investigated in an experiment where unilateral
renal infection was induced in a group of 144 ani-
mals which were treated with gentamicin for 11
days starting 7 days after challenge. Animals were
killed 1, 4, 7, 11, and 18 days after the cessation of
treatment, and both left and right kidneys were re-
moved. Gentamicin accumulation was demon-
strable in all the kidneys examined up to 18 days
after the cessation of treatment. Mean concentra-
tions of 35 g/ml were found during the first 4 days
after the cessation of treatment, but bactericidal
levels persisted in the tissue up to 18 days later.
There were no significant differences in the concen-
tration of gentamicin retained by the unmanipulated
normal contralateral kidney and the pyelonephritic
Absolute Ostensible j Procedural control
groupEradication of infection
Gentamicin treated
f
Urine
I
10
9
8
7
C65
E
a
3
2
50
40
30
20
a)(6
Serum
I
.1
TI
I
I
I I
241 1 1! 2 21 102 2 2
Time after gentamicin administration, hr
Fig. 1. Serum and urinary concentrations of antibiotic attained
after the i.m. administration of 15 mg/kg of gentamicin. The fig-
ures for each time period are the mean I SD of the results
obtained from 6 animals.
.
S.
.
S.
S
.
S
S
.
S
•5S
6
5
C0
0
S
0C
.is 3
Ca
-D
0
(a
=
0(0
-J
Nontreated
Pyelonephritic animals
Fig. 2. 'Ostensible" eradication of renal infection by gentamicin
therapy. Of the 56 experimental animals examined in this experi-
ment and found to be sterile on initial examination, only 15 (ab-
solute eradication) remained sterile when dilutions of the kidney
homogenate were cultured. In 37 of the remaining 41 animals,
eradication of infection was "ostensible" in that up to a 10,000-
fold increase in the number of microorganisms in the kidney
were demonstrable when homogenized preparations of renal tis-
sue were diluted before bacteriologic culture.
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gan 7 days after challenge and was continued for II
days. Animals were killed 1,4, Ii, and 18 days after
the final day of gentamicin treatment, and the kid-
neys were removed and bisected to separate the up-
per and lower poles. The renal lesions, however,
did not influence the distribution of gentamicin, and
similar concentrations of the antimicrobial agent
were found in both poles of the kidney from 1 to 18
days after the cessation of treatment (Fig. 5), al-
though it should be appreciated that the methodolq-
gy may not be sufficiently sensitive to detect
changes in neighboring areas in the vicinity of in-
fected tissue. In an additional experiment, the gross
pathologic and histopathologic features of the le-
sions in the kidneys of animals challenged in the up-
per pole of one kidney were determined (Fig. 6).
Site of gentamicin and E. coli localization within
the kidney. Local sequestration resulting in a gradi-
ent of gentamicin within the kidney could explain
the ostensible eradication of infection reported in
Fig. 2. Renal infection was induced in two groups of
animals, both of which were treated with gen-
tamicin (15 mg/kg) for 11 days starting I week after
challenge. The two groups were killed 7 and 11 days
after cessation of treatment, and the concentration
of gentamicin and the number of residual micro-
organisms in the renal cortex and medulla were de-
termined. The concentration of gentamicin in the
renal cortex in animals examined 7 days after the
cessation of therapy was significantly higher than it
was in medullary tissue from the same animals (P <
0.01, by Wilcoxon sum of ranks analysis; Fig. 7).
Renal infection had been eradicated from cortical
tissue in 21 out of 24 of the animals challenged
(88%), whereas medullary tissue was found to be
sterile in only 7 out of 24 cases (29%). Similar re-
sults were obtained when renal tissue was examined
11 days after the cessation of therapy.
Discussion
Our biologic experiments and the observation
that eradication of renal infection following gen-
tamicin therapy was apparent rather than real led us
to conclude that the reciprocal relationship between
the site of bacterial persistence and the concentra-
tion of antimicrobial agent in the kidney explained
how infection of the retal parenchyma could be
maintained despite the presence of apparently bac-
tericidal concentrations of gentamicin.
Although antibiotics show remarkable variations
in their ability to concentrate in different tissues,
the accumulation and persistence of the amino-
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Fig. 3. Effect ofpyelonephritis on the concentration ofgentamicin in renal tissue. Animals with unilateral pyelonephritis were killed from
1 to 18 days after the termination of an 11-day course of gentamicin (15 mg/kg/day), and the concentrations of gentamicin in the pyelo-
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Fig. 4. Urinary excretion of gentamicin after the termination of
antimicrobial therapy. Bactericidal levels of the antimicrobial
agent could be demonstrated in the urine up to 7 days after cessa-
tion of therapy and were still detectable 18 days later.
glycosides by renal tissue appear to be unique. The
suggestion that gentamicin may accumulate in the
kidney was first reported in 1974 by Whelton and
Walker [9] and was commented on by Kahimeter
and Kamme [10] in a letter to Lancet claiming that
they were able to detect the antibiotic in urine 20
days after therapy had been discontinued. Wahlig
[111 later confirmed this observation experimentally
by showing that the bulk of the antibiotic was ex-
creted in the urine within 24 hours but slow excre-
tion continued for several days after serum concen-
trations had become undetectable. These findings
have been confirmed and extended by the direct ex-
amination of gentamicin levels in the tissue of
experimental animals [12, 13] and in the genito-
urinary tissue in man 1141 during studies of the
pharmacokinetics of gentamicin. An important
feature of our experiments has been the disclosure
of a reciprocal relationship between the site of bac-
terial persistence and the concentration of anti-
microbial agent in the kidney which has provided an
explanation for the persistence of renal infection,
despite seemingly adequate concentrations of gen-
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tamicin in serum, urine, and renal tissue. The con-
cept of a reciprocal relationship between bacterial
persistence and antimicrobial concentration in cor-
tical and medullary tissue arose from our observa-
tions of the distribution of gentamicin and micro-
organisms in renal tissue after therapy had been dis-
continued. The distribution of gentamicin within the
kidney during therapy was not determined in the
present experiments; however, the pharmacoki-
netics found by us during the posttherapy peri-
od are similar to those observed by Fabre et al [131
in the period immediately following the administra-
tion of gentamicin, and it is reasonable to assume
that a marked cortical-medullary gradient was also
present in our animals during gentamicin adminis-
tration. The experiments have shown that bacteri-
cidal concentrations of gentamicin were still present
in the renal cortex at least 14 days after therapy had
been discontinued, and as a result of the high con-
centration of gentamicin, cortical tissue was usually
sterile. Bacterial persistence, however, was found
in the medulla where the concentration of the anti-
microbial agent was comparatively low. The rela-
tionship between the site of bacterial persistence
and antimicrobial concentration was not absolute,
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Fig. 5. Effect of pyelonephritis on the intrarenal distribution of
gentamicin. Pyelonephritis was established in the upper pole of
individual kidneys, and the animals were killed ito 18 days after
the cessation of gentamicin treatment.
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Fig. 6. Gross and histopathologic changes in the kidneys of ex-
perimental animals challenged in the upper pole only. Quan-
titation of the gross pathology was made on a 0 to 10 scale, with
each unit of the scale representing one tenth of the surface of the
kidney. In the case of histopathology, 10 represented lesions in-
volving 25% or more of the area of the section. Lesser degrees of
damage were scored on a 0 to 10 scale, where each unit repre-
sented 2.5% of the area of the kidney.
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Fig. 7. Localization of gentamicin and E. coli within the kidney.
Renal infection was induced in two groups of animals which were
treated with gentamicin and killed 7 days after treatment had
ceased. Quantitative analysis of the distribution of E. coil and
gentamicin in the renal cortex and medulla shows a reciprocal
relationship between the concentration of antimicrobial agent in
the kidney and the site of bacterial persistence. The vertical bars
in the right-hand frame of the figure represent the full range of
bacterial counts in the cortex and medulla of 12 untreated ani-
mals challenged and examined at the same time as the experi-
mental group.
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but this was to be expected. The procedure for the
division of the kidney into cortical and medullary
tissue was essentially a macroscopic dissection, and
some admixture of the pericortical zone of cortical
and medullary tissue would have occurred with in-
dividual dissections. Nevertheless 88% of cortical
tissue sectioned was sterile, whereas infection was
eradicated in only 29% of the medullary tissue ex-
amined. The other major contribution of the pres-
ent study has been to determine the effect of a
renal infection on the ability of gentamicin to reach
therapeutically effective levels in the pyelonephritic
kidney. With an experimental model, the concen-
tration of gentamicin was shown to be similar in
both the pyelonephritic and the contralateral un-
challenged kidney, and similar results were ob-
tained when the gentamicin content of normal and
pathologically altered tissue within the pyelonephritic
kidney was studied. The procedures used in these
analyses, however, were not sufficiently sensitive
to exclude the possibility that in neighboring areas
within the local environment of an infected site, the
concentration of gentamicin would not be affected
by pathologic damage to the kidney. Further studies
using autoradiographic procedures to localize radio-
actively labeled gentamicin will be needed to re-
solve this question.
The biologic significance of the renal accumula-
tion of gentamicin has not been widely recognized,
although Whelton and others have attempted to de-
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termine the therapeutic implications in severe renal
.. disease [15J. Chronic diseases in the kidney may
present a significant barrier to the penetration of
some antibiotics into the kidney, and in the case of
gentamicin, substantially reduced concentrations
• have been found in diseased kidneys. Most of the
• available information, however, has been derived
from studies of human kidneys with end-stage renal
disease unrelated to the pathologic changes found in
Infected Noninfected renal infection [161 and the present experiments
tissue tissue demonstrate the ability of a relevant experimental
model to provide information on the pharma-
cokinetics of gentamicin in a localized infectious le-
sion. The cellular or subcellular site of gentamicin
accumulation has not been determined, although
the binding appears to be associated with the partic-
ulate cell fractions [171. The changes described by
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Patel et al 18i and Kosek et al Ii19], who used the
electron microscope to show cytosegrosomes with
mye!oid bodies within the proximal tubular cells,
may be of significance, but the association between
renal cortical aminoglycoside accumulation and
cytosegrosome formation must await the precise in-
tracellular location of the aminoglycoside antibiot-
ics.
The demonstration that organisms may persist in
renal tissue despite apparently bactericidal levels of
antimicrobial agent is an observation of some years
standing 2O]. The most logical explanation is that
the concentrations of antimicrobial agent deter-
mined quantitatively in blood, tissue, and urine
samples, which in the present experiments were 5,
25, and 28 times the minimum bactericidal concen-
tration of the infecting organism, do not approxi-
mate the concentration of gentamicin actually
achieved at the site of microbial sequestration. Our
interpretation of the relationship between cortical
and medullary concentrations of gentamicin and the
bacteriologic status of the kidney is that the concen-
tration of antimicrobial agent present in these ana-
tomical sites, when determined by current proce-
dures, represents only the comparative potential of
the antibiotic to achieve a bactericidal concentra-
tion at the site of infection. The simple achievement
of a bactericidal tissue concentration of an anti-
microbial agent, even when favorably related to the
minimum bactericidal concentration of the infecting
organism, is not an accurate predictor of the ability
of an antimicrobial agent to eradicate a local renal
infection.
In summary, a study of the gradient patterns of
gentamicin and microorganisms following experi-
mentally induced and treated renal infection has
provided an explanation for the observation that in-
fection in the kidney may persist despite adequate
therapy with appropriately selected antimicrobial
agents. The experiments have emphasized the im-
portance of considering the anatomic, pharmaco-
logic, and bacteriologic features of the local envi-
ronment in the management of renal infection.
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